Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | ITGAV | P06756 | 2/20 | 0.50 |
| ▸ | ECE1 | P42892 | 2/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065343 | 0.91 | SIRT2 (0.56) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL8387978 | 0.87 | FOLH1 (0.65) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL10421088 | 0.87 | FOLH1 (0.62) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL25365812 | 0.86 | CTSL (0.58) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL25365816 | 0.86 | CTSL (0.58) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL18762518 | 0.85 | SIRT2 (0.57) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL15666217 | 0.85 | SIRT2 (0.57) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL15666216 | 0.85 | SIRT2 (0.57) | SIRT2SIRT1CTSLCTSSITGB3 | |
| SCHEMBL11332452 | 0.84 | CTSL (0.72) | SIRT2SIRT1CTSLCTSSFOLH1 | |
| SCHEMBL4126228 | 0.84 | CTSL (0.72) | SIRT2SIRT1CTSLCTSSFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203420-A1 | HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| WO-2009042093-A1 | HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | PRSS1, FURIN, SERPINB1 | SIRT2 1673/4885SIRT1 474/4885CTSL 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.